Overview

Naloxone for Optimizing Hypoxemia Of Lung Donors

Status:
Completed
Trial end date:
2017-09-25
Target enrollment:
Participant gender:
Summary
Brain-dead patients who provide authorization for organ donation will be randomized to naloxone or placebo if baseline arterial blood gas (ABG) after initiation of OPO (Organ Procurement Organization) management reveals hypoxemia, as defined by the ratio of partial pressure of oxygen in arterial blood (PaO2) to fraction of inspired oxygen (FiO2) below 300 mm Hg, unless they have already been ruled-out for lung recovery. Investigators aim to assess whether naloxone improves oxygenation prior to organ recovery more than placebo.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Naloxone